Document Detail

Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction.
MedLine Citation:
PMID:  11929349     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To compare the costs to the Spanish healthcare system of 35 days' treatment with triflusal (600 mg/day) and aspirin (300 mg/day) in patients with confirmed acute myocardial infarction within 24 hours of onset of symptoms. DESIGN: A cost minimisation analysis based on the results of the Triflusal in Acute Myocardial Infarction study (TIM) was conducted. The hypothesis was that despite a higher acquisition cost of triflusal, savings would result because of differences in efficacy and safety outcome (non-fatal cerebrovascular event and haemorrhagic events). Diagnostic Related Groups were used as a proxy for determining hospital costs in Spain and the values were obtained from different sources and refer to year 2000 costs. Only direct medical costs were considered for the economic analysis. RESULTS: Although the acquisition cost of triflusal was more expensive than that of aspirin, the cost of prevented events - non-fatal ischaemic cerebrovascular events and cerebral haemorrhages - entirely compensated for the cost of triflusal. The overall cost of treating patients with triflusal, compared with aspirin, represented a net saving of 28.4% per patient treated. CONCLUSION: Our study showed that triflusal is cost saving compared with aspirin in the treatment of the acute phase of myocardial infarction.
Josep Darbà; Iñaki Izquierdo; Caridad Pontes; Carlos Navas; Joan Rovira
Related Documents :
9823789 - Advances in the medical management of acute coronary syndromes.
19804099 - Clopidogrel plus aspirin in patients with acute myocardial infarction treated with fibr...
10731289 - Combination enoxaparin and abciximab therapy during percutaneous coronary intervention:...
7545449 - Effects of aprotinin on blood loss, heparin monitoring tests, and heparin doses in pati...
19738549 - Prasugrel (effient) vs. clopidogrel (plavix).
9779029 - Management of acute coronary syndromes with low molecular weight heparin: timi 11a and ...
7507999 - Interstitial collagen is increased in the non-infarcted human myocardium after myocardi...
19069369 - Outcomes after heart valve replacement surgery at the cardiovascular center of puerto r...
18391729 - Myocardial scar and insulin resistance predict cardiovascular events in severe ischaemi...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  PharmacoEconomics     Volume:  20     ISSN:  1170-7690     ISO Abbreviation:  Pharmacoeconomics     Publication Date:  2002  
Date Detail:
Created Date:  2002-04-03     Completed Date:  2002-06-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9212404     Medline TA:  Pharmacoeconomics     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  195-201     Citation Subset:  T    
Department of Economy, University of Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Disease
Aspirin / economics*,  therapeutic use*
Double-Blind Method
Drug Costs
Myocardial Infarction / drug therapy*,  economics*
Platelet Aggregation Inhibitors / economics*,  therapeutic use*
Salicylates / economics*,  therapeutic use*
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 0/Salicylates; 322-79-2/triflusal; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Development of an economic model to assess the cost effectiveness of asthma management strategies.
Next Document:  Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arteri...